Bulk Manufacturer of Controlled Substances Application: Arista Biologicals, 3694-3695 [2024-00994]
Download as PDF
<![CDATA[
ddrumheller on DSK120RN23PROD with NOTICES1
3694
Federal Register / Vol. 89, No. 13 / Friday, January 19, 2024 / Notices
filed on behalf of, and (4) whether it
contains CBI. If it contains CBI, it must
comply with the marking and other
requirements set out below in this
notice relating to CBI. Submitters of
written documents (other than oral
hearing statements) are encouraged to
include a short summary of their
position or interest at the beginning of
the document, and a table of contents
when the document addresses multiple
issues.
Confidential Business Information:
Any submissions that contain CBI must
also conform to the requirements of
section 201.6 of the Commission’s Rules
of Practice and Procedure (19 CFR
201.6). Section 201.6 of the rules
requires that the cover of the document
and the individual pages be clearly
marked as to whether they are the
‘‘confidential’’ or ‘‘nonconfidential’’
version, and that the CBI is clearly
identified by means of brackets. All
written submissions, except for CBI,
will be made available for inspection by
interested persons.
As requested by the Trade
Representative, the Commission will not
include any CBI in its report. However,
all information, including CBI,
submitted in this investigation may be
disclosed to and used by: (i) the
Commission, its employees and offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission, including under 5
U.S.C. appendix 3; or (ii) U.S.
government employees and contract
personnel for cybersecurity purposes.
The Commission will not otherwise
disclose any CBI in a way that would
reveal the operations of the firm
supplying the information.
Summaries of Written Submissions:
Persons wishing to have a summary of
their position included in the report
should include a summary with their
written submission on or before March
22, 2024, and should mark the summary
as having been provided for that
purpose. The summary should be
clearly marked as ‘‘summary for
inclusion in the report’’ at the top of the
page. The summary may not exceed 500
words and should not include any CBI.
The summary will be published as
provided if it meets these requirements
and is germane to the subject matter of
the investigation. The Commission will
list the name of the organization
furnishing the summary and will
include a link where the written
submission can be found.
VerDate Sep<11>2014
18:42 Jan 18, 2024
Jkt 262001
By order of the Commission.
Issued: January 16, 2024.
Lisa Barton,
Secretary to the Commission.
notice is published pursuant to section
201.10 of the Commission’s rules (19
CFR 201.10).
[FR Doc. 2024–00999 Filed 1–18–24; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
By order of the Commission.
Issued: January 12, 2024.
Sharon Bellamy,
Supervisory Hearings and Information
Officer.
[FR Doc. 2024–00911 Filed 1–18–24; 8:45 am]
BILLING CODE 7020–02–P
[Investigation Nos. 731–TA–1602, 1604–
1606 (Final)]
Tin Mill Products From the
Netherlands, Taiwan, Turkey, and the
United Kingdom Termination of
Investigations
United States International
Trade Commission.
ACTION: Notice.
AGENCY:
On January 10, 2024, the
Department of Commerce published
notice in the Federal Register of
negative final determinations of less
than fair value (LTFV) in connection
with the subject investigations
concerning the Netherlands, Taiwan,
Turkey, and the United Kingdom.
Accordingly, the antidumping duty
investigations concerning tin mill
products from the Netherlands, Taiwan,
Turkey, and the United Kingdom
(Investigation Nos. 731–TA–1602, 1604–
1606 (Final)) are terminated.
DATES: January 10, 2024.
FOR FURTHER INFORMATION CONTACT:
Caitlyn Hendricks-Costello (202–205–
2058), Office of Investigations, U.S.
International Trade Commission, 500 E
Street SW, Washington, DC 20436.
Hearing-impaired individuals are
advised that information on this matter
can be obtained by contacting the
Commission’s TDD terminal on 202–
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202–205–2000.
General information concerning the
Commission may also be obtained by
accessing its internet server (https://
www.usitc.gov). The public record for
these investigations may be viewed on
the Commission’s electronic docket
(EDIS) at https://edis.usitc.gov.
Notice of these determinations was
published in the Federal Register on
January 10, 2024 at 89 FR 1524, 89 FR
1526, 89 FR 1520, and 89 FR 1535.
Authority: These investigations are
being terminated under authority of title
VII of the Tariff Act of 1930 and
pursuant to section 207.40(a) of the
Commission’s Rules of Practice and
Procedure (19 CFR 207.40(a)). This
SUMMARY:
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1311]
Bulk Manufacturer of Controlled
Substances Application: Arista
Biologicals
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Arista Biologicals has applied
to be registered as a bulk manufacturer
of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before March 19, 2024. Such
persons may also file a written request
for a hearing on the application on or
before March 19, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on November 28, 2023,
Arista Biologicals, 1101 Hamilton
Street, Allentown, Pennsylvania 18101–
1043 applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUMMARY:
E:\FR\FM\19JAN1.SGM
19JAN1
Federal Register / Vol. 89, No. 13 / Friday, January 19, 2024 / Notices
Controlled substance
4-Anilino-N-Phenethyl-4Piperidine (ANPP).
Norfentanyl (N-phenyl-N(piperidin-4-yl)
propionamide).
Drug
code
Schedule
8333
II
8366
II
The company plans to bulk
manufacture the listed controlled
substances for the internal use as
intermediates for formulation and
analytical development purposes. No
other activities for these drug codes are
authorized for this registration.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–00994 Filed 1–18–24; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1310]
Bulk Manufacturer of Controlled
Substances Application: Siegfried
USA, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Siegfried USA, LLC has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before March 19, 2024. Such
persons may also file a written request
for a hearing on the application on or
before March 19, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:42 Jan 18, 2024
Jkt 262001
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on November 28, 2023,
Siegfried USA, LLC, 33 Industrial Park
Road, Pennsville, New Jersey 08070–
3244, applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
Controlled substance
Gamma Hydroxybutyric
Acid.
Noroxymorphone .............
Hydromorphinol ...............
Amphetamine ..................
Lisdexamfetamine ...........
Methylphenidate ..............
Amobarbital .....................
Pentobarbital ...................
Secobarbital .....................
Codeine ...........................
Oxycodone ......................
Hydromorphone ...............
Hydrocodone ...................
Methadone ......................
Methadone intermediate ..
Morphine ..........................
Oripavine .........................
Thebaine ..........................
Opium tincture .................
Oxymorphone ..................
Tapentadol ......................
Drug
code
Schedule
2010
I
9145
9301
1100
1205
1724
2125
2270
2315
9050
9143
9150
9193
9250
9254
9300
9330
9333
9630
9652
9780
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to bulk
manufacture the listed controlled
substances in bulk for sale to its
customers. No other activities for these
drug codes are authorized for this
registration.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–00990 Filed 1–18–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF LABOR
Bureau of Labor Statistics
Information Collection Activities;
Comment Request
Bureau of Labor Statistics,
Department of Labor.
ACTION: Notice of information collection;
request for comment.
AGENCY:
The Department of Labor, as
part of its continuing effort to reduce
paperwork and respondent burden,
conducts a pre-clearance consultation
program to provide the general public
and Federal agencies with an
opportunity to comment on proposed
and/or continuing collections of
information in accordance with the
Paperwork Reduction Act of 1995. This
SUMMARY:
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
3695
program helps to ensure that requested
data can be provided in the desired
format, reporting burden (time and
financial resources) is minimized,
collection instruments are clearly
understood, and the impact of collection
requirements on respondents can be
properly assessed. The Bureau of Labor
Statistics (BLS) is soliciting comments
concerning the proposed revision of the
International Price Program (IPP) U.S.
Import and Export Price Indexes. A
copy of the proposed information
collection request can be obtained by
contacting the individual listed below
in the ADDRESSES section of this notice.
DATES: Written comments must be
submitted to the office listed in the
Addresses section of this notice on or
before March 19, 2024.
ADDRESSES: Send comments to Nora
Kincaid, BLS Clearance Officer,
Division of Management Systems,
Bureau of Labor Statistics, Room G225,
2 Massachusetts Avenue NE,
Washington, DC 20212. Written
comments also may be transmitted by
email to BLS_PRA_Public@bls.gov.
FOR FURTHER INFORMATION CONTACT:
Nora Kincaid, BLS Clearance Officer, at
202–691–7628 (this is not a toll free
number). (See ADDRESSES section.)
SUPPLEMENTARY INFORMATION:
I. Background
The U.S. Import and Export Price
Indexes, produced by the Bureau of
Labor Statistics’ International Price
Program (IPP), measure price change
over time for all categories of imported
and exported products, as well as
selected services. The IPP has produced
the U.S. Import Price Indexes (MPI)
continuously since 1973 and the U.S.
Export Price Indexes (XPI) continuously
since 1971. The Office of Management
and Budget has listed the Import and
Export Price Indexes (MXPI) as a
Principal Federal Economic Indicator
since 1982. The indexes are widely used
in both the public and private sectors.
The primary public sector use is the
deflation of the U.S. monthly trade
statistics and the quarterly estimates of
U.S. Gross Domestic Product; the
indexes also are used in formulating
U.S. trade policy and in trade
negotiations with other countries. In the
private sector, uses of the Import Price
Indexes include market analysis,
inflation forecasting, contract escalation,
and replacement cost accounting.
The MXPI are closely followed
statistics and are viewed as a key
indicator of the economic environment.
The U.S. Department of Commerce uses
the monthly statistics to produce
monthly and quarterly estimates of
E:\FR\FM\19JAN1.SGM
19JAN1
]]>Agencies
[Federal Register Volume 89, Number 13 (Friday, January 19, 2024)]
[Notices]
[Pages 3694-3695]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00994]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1311]
Bulk Manufacturer of Controlled Substances Application: Arista
Biologicals
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Arista Biologicals has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
March 19, 2024. Such persons may also file a written request for a
hearing on the application on or before March 19, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on November 28, 2023, Arista Biologicals, 1101 Hamilton
Street, Allentown, Pennsylvania 18101-1043 applied to be registered as
a bulk manufacturer of the following basic class(es) of controlled
substance(s):
[[Page 3695]]
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
4-Anilino-N-Phenethyl-4-Piperidine 8333 II
(ANPP).
Norfentanyl (N-phenyl-N-(piperidin-4-yl) 8366 II
propionamide).
------------------------------------------------------------------------
The company plans to bulk manufacture the listed controlled
substances for the internal use as intermediates for formulation and
analytical development purposes. No other activities for these drug
codes are authorized for this registration.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2024-00994 Filed 1-18-24; 8:45 am]
BILLING CODE 4410-09-P
